Synermore Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 90


  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $27.6M

  • Investors
  • 2

Synermore General Information


Developer of biotechnology services intended to focus on research and development of innovative and biosimilar monoclonal antibodies. The company's services primary researches to bring products from research stage through IND-enabling nonclinical and CMC activities to clinical stage of development, enabling clients to launch their products with certification.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Other Healthcare Services
Corporate Office
  • 6F-6, Number 5
  • Alley 22, Lane 513, Ruiquang Road
  • Taipei, 114-92
  • Taiwan
+886 02 0000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Synermore Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 01-Dec-2016 $27.6M 000.00 Completed Clinical Trials - Phase 1
2. Early Stage VC 11-Feb-2015 00.000 000.00 Completed Generating Revenue
1. Early Stage VC $20.6M $20.6M Completed Generating Revenue
To view Synermore’s complete valuation and funding history, request access »

Synermore Patents

Synermore Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
ES-2804826-T3 Anti-egfr antibody and uses of it Active 16-Sep-2014 00000000000
EP-3110447-A1 Anti-egfr antibody and uses of same Active 16-Sep-2014 00000000000
EP-3110447-B1 Anti-egfr antibody and uses of same Active 16-Sep-2014 00000000000
EP-3110447-A4 Anti-egfr antibody and uses of same Active 16-Sep-2014 C07K16/2863 0

Synermore Executive Team (2)

Name Title Board Seat Contact Info
Eric Tsao Ph.D Chief Executive Officer
Perky Huang Chief Financial Officer
To view Synermore’s complete executive team members history, request access »

Synermore Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Synermore Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
CDIB Capital Group Venture Capital Minority 000 0000 000000 0
Morningside Group Venture Capital Minority 000 0000 000000 0
To view Synermore’s complete investors history, request access »

Synermore Subsidiaries (1)

Company Name Industry Location Founded
Long Rui Pharma Biotechnology Shenzhen, China 0000
To view Synermore’s complete subsidiaries history, request access »

Synermore FAQs

  • When was Synermore founded?

    Synermore was founded in 2013.

  • Who is the CEO of Synermore?

    Eric Tsao Ph.D is the CEO of Synermore.

  • Where is Synermore headquartered?

    Synermore is headquartered in Taipei, Taiwan.

  • What is the size of Synermore?

    Synermore has 90 total employees.

  • What industry is Synermore in?

    Synermore’s primary industry is Biotechnology.

  • Is Synermore a private or public company?

    Synermore is a Private company.

  • What is Synermore’s current revenue?

    The current revenue for Synermore is 00000.

  • How much funding has Synermore raised over time?

    Synermore has raised $56.4M.

  • Who are Synermore’s investors?

    CDIB Capital Group and Morningside Group have invested in Synermore.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »